Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

PainReform Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ACQUISITION OF MAJORITY EQUITY INTEREST IN LAYERBIO AND ITS OCURING-K TECHNOLOGY TARGETS GROWING DEMAND FOR DROPLESS' SOLUTIONS IN OPHTHALMIC SURGERY ACQUISITION OF MAJORITY EQUITY INTEREST IN LAYERBIO AND ITS OCURING-K TECHNOLOGY TARGETS GROWING DEMAND FOR DROPLESS' SOLUTIONS IN OPHTHALMIC SURGERY

PAINREFORM LTD. COMPLETES STRATEGIC INVESTMENT IN LAYERBIO TO ENTER $9B GLOBAL CATARACT SURGERY MARKET WITH BREAKTHROUGH NON-OPIATE, NON-STEROIDAL POSTOPERATIVE NSAID DRUG DELIVERY SYSTEM

TEL AVIV, ISRAEL, JULY 10, 2025 (GLOBE NEWSWIRE) -- PAINREFORM LTD. (NASDAQ: PRFX), TODAY ANNOUNCED, THROUGH ITS PHARMACEUTICAL DIVISION, THE SIGNING OF A STRATEGIC INVESTMENT AGREEMENT WITH LAYERBIO INC., A PRIVATELY HELD BOSTON BIOTECHNOLOGY COMPANY DEVELOPING PROPRIETARY, LONG-ACTING, NON-OPIATE TREATMENTS FOR OPHTHALMIC SURGERY.

PAINREFORM LTD. ENTERS INTO A STRATEGIC INVESTMENT AGREEMENT TO EXPAND ITS NON-OPIATE PAIN MANAGEMENT PIPELINE INTO OPTHAMOLOGY WITH LAYERBIO

AS A RESULT OF INCREASED SOFTWARE SALES BY THE ACQUIRER, AND IN ACCORDANCE WITH THE TERMS OF THE SOFTWARE BUSINESS SALE AGREEMENT, A SIGNIFICANT NUMBER OF ZERO-EXERCISE-PRICE WARRANTS HAVE MATUREDBLADE RANGER NOW HOLDS APPROXIMATELY 1 MILLION SHARES AND WARRANTS EXERCISABLE AT NO ADDITIONAL COST TEL AVIV, ISRAEL , MAY 27, 2025 /PRNEWSWIRE/ -- BLADE RANGER LTD. (TASE: BLRN), A COMPANY LISTED ON THE TEL AVIV STOCK EXCHANGE, ANNOUNCED THE ACHIEVEMENT OF A FIRST MILESTONE IN THE TRANSACTION INVOLVING THE SALE OF ITS DEEPSOLAR OPERATIONS TO PAINREFORM (NASDAQ: PRFX).

BLADE RANGER: CONSIDERATION FROM PAINREFORM TRANSACTION CONTINUES TO MATURE FOLLOWING GROWTH IN SOFTWARE SALES

TEL AVIV, ISRAEL, MAY 07, 2025 (GLOBE NEWSWIRE) -- PAINREFORM LTD. (NASDAQ: PRFX), TODAY ANNOUNCED THE LAUNCH OF A STRATEGIC PILOT PROGRAM WITH ECONERGY RENEWABLE ENERGY LTD., A LEADING EUROPEAN INDEPENDENT POWER PRODUCER (IPP). THE PROJECT WILL UTILIZE PAINREFORM'S PROPRIETARY DEEPSOLAR PLATFORM, AN AI-POWERED OPTIMIZATION SOLUTION DESIGNED TO ENHANCE OPERATIONAL EFFICIENCY AND ENERGY YIELD AT UTILITY-SCALE SOLAR FACILITIES. THE PILOT WILL BE CONDUCTED AT ECONERGY'S 92-MEGAWATT (MW) PHOTOVOLTAIC PLANT IN PARAU, ROMANIAONE OF THE COUNTRY'S LARGEST OPERATIONAL SOLAR PROJECTS.

PAINREFORM LAUNCHES STRATEGIC AI PILOT WITH ECONERGY USING ITS PROPRIETARY DEEPSOLAR PLATFORM TO OPTIMIZE ONE OF ROMANIA'S LARGEST SOLAR PROJECTS

TEL AVIV, ISRAEL, APRIL 10, 2025 (GLOBE NEWSWIRE) -- PAINREFORM LTD. (NASDAQ: PRFX), A CLINICAL-STAGE SPECIALTY PHARMACEUTICAL COMPANY AND DEVELOPER OF AI-POWERED ENERGY OPTIMIZATION TECHNOLOGIES, TODAY ANNOUNCED ITS OFFICIAL EXPANSION INTO THE RAPIDLY GROWING SMART ENERGY MANAGEMENT (SEM) SECTOR. THIS MOVE FOLLOWS THE SUCCESSFUL ACQUISITION OF DEEPSOLAR, A CUTTING-EDGE PROVIDER OF AI-DRIVEN SOFTWARE SOLUTIONS DESIGNED TO OPTIMIZE SOLAR ENERGY USAGE IN RESIDENTIAL AND UTILITY-SCALE SOLAR POWER PLANTS.

PAINREFORM EXPANDS INTO HOME ENERGY MANAGEMENT SECTOR, LEVERAGING DEEPSOLAR'S AI-DRIVEN PLATFORM TO ADDRESS THE GROWING SOLAR OPTIMIZATION MARKET

TEL AVIV, ISRAEL, APRIL 07, 2025 (GLOBE NEWSWIRE) -- PAINREFORM LTD. (NASDAQ: PRFX) ("PAINREFORM" OR THE "COMPANY"), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE REFORMULATION OF ESTABLISHED THERAPEUTICS AND COMMERCIALIZATION OF THE DEEPSOLAR ACTIVITIES, TODAY PROVIDED A BUSINESS UPDATE FOR THE YEAR ENDED DECEMBER 31, 2024.

PAINREFORM PROVIDES YEAR-END BUSINESS UPDATE

ACQUISITION POSITIONS PAINREFORM AS A POTENTIAL LEADER IN HIGH-GROWTH, HIGH-MARGIN AI SOLAR ENERGY MANAGEMENT WHILE CONTINUING ITS CORE FOCUS ON PHARMACEUTICAL INNOVATION ACQUISITION POSITIONS PAINREFORM AS A POTENTIAL LEADER IN HIGH-GROWTH, HIGH-MARGIN AI SOLAR ENERGY MANAGEMENT WHILE CONTINUING ITS CORE FOCUS ON PHARMACEUTICAL INNOVATION

PAINREFORM COMPLETES STRATEGIC ACQUISITION OF DEEPSOLAR, UNLOCKING NEW GROWTH OPPORTUNITIES IN AI-DRIVEN SOLAR ANALYTICS

DEEPSOLAR BRINGS NEW CUSTOMER BASE IN CREATION, INCLUDING MAJOR UTILITY-SCALE SOLAR OPERATORS AND INDEPENDENT POWER PRODUCERS, WHILE BREAKING INTO THE RESIDENTIAL SOLAR MARKET THE COMPANY REMAINS COMMITTED TO ADVANCING ITS DRUG DELIVERY TECHNOLOGIES WHILE BROADENING ITS GROWTH POTENTIAL TEL AVIV, ISRAEL, FEB. 18, 2025 (GLOBE NEWSWIRE) -- PAINREFORM LTD. (NASDAQ: PRFX) ("PAINREFORM" OR THE "COMPANY"), A CLINICAL-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE REFORMULATION OF ESTABLISHED THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS EXECUTED A DEFINITIVE AGREEMENT WITH BLADERANGER LTD, A PUBLIC COMPANY REGISTERED UNDER THE LAWS OF THE STATE OF ISRAEL, WHOSE SHARES ARE LISTED FOR TRADING ON TEL AVIV STOCK EXCHANGE UNDER THE TICKER BLRN (THE BLRN) TO ACQUIRE 100% OF THE BUSINESS ACTIVITY OF DEEPSOLAR, AN AI-DRIVEN SOLAR ANALYTICS PLATFORM OWNED BY BLRN (THE AGREEMENT).

PAINREFORM EXECUTES DEFINITIVE AGREEMENT TO ACQUIRE DEEPSOLAR, MARKING A UNIQUE EXPANSION OPPORTUNITY

TEL AVIV, ISRAEL, DEC. 27, 2024 (GLOBE NEWSWIRE) -- PAINREFORM LTD. (NASDAQ: PRFX) ("PAINREFORM" OR THE "COMPANY"), A CLINICAL-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE REFORMULATION OF ESTABLISHED THERAPEUTICS, TODAY ANNOUNCED AN UPDATE REGARDING ITS PHASE 3 CLINICAL TRIAL EVALUATING PRF-110 IN POST-SURGICAL PAIN MANAGEMENT OF PATIENTS UNDERGOING BUNIONECTOMY.

PAINREFORM PROVIDES FURTHER UPDATE ON PHASE 3 CLINICAL TRIAL OF PRF-110

TEL AVIV, ISRAEL, NOV. 20, 2024 (GLOBE NEWSWIRE) -- PAINREFORM LTD. (NASDAQ: PRFX) ("PAINREFORM" OR THE "COMPANY"), A CLINICAL-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE REFORMULATION OF ESTABLISHED THERAPEUTICS, TODAY ANNOUNCED THE RECEIPT OF PARTIAL TOPLINE DATA FROM ITS CONTRACT RESEARCH ORGANIZATION (CRO), LOTUS CLINICAL RESEARCH ("LOTUS"), FOR THE PHASE 3 CLINICAL TRIAL EVALUATING PRF-110 IN POST-SURGICAL PAIN MANAGEMENT OF PATIENTS UNDERGOING BUNIONECTOMY.

PainReform Ltd.

PRFX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PainReform Ltd.

PRFX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PRFX